Guggenheim Capital LLC Veracyte, Inc. Transaction History

Guggenheim Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$15.31 - $29.94 $56,953 - $111,376	-3,720 Reduced 8.17%	41,791 $991,000
Q3 2022 Nov 14, 2022	SELL	$16.58 - $27.9 $72,056 - $121,253	-4,346 Reduced 8.72%	45,511 $755,000
Q2 2022 Aug 15, 2022	BUY	$15.45 - $29.52 $93,271 - $178,212	6,037 Added 13.78%	49,857 $992,000
Q1 2022 May 16, 2022	BUY	$21.94 - $42.51 $160,469 - $310,918	7,314 Added 20.04%	43,820 $1.21 Million
Q4 2021 Feb 14, 2022	BUY	$36.09 - $53.79 $89,936 - $134,044	2,492 Added 7.33%	36,506 $1.5 Million
Q3 2021 Nov 15, 2021	SELL	$35.62 - $52.97 $157,369 - $234,021	-4,418 Reduced 11.5%	34,014 $1.58 Million
Q2 2021 Aug 13, 2021	BUY	$32.94 - $56.62 $1.27 Million - $2.18 Million	38,432 New	38,432 $1.54 Million

311

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.9B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.